Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Fevzi Altuntas and Mehmet Dal.
Fevzi Altuntas
Connection Strength
2.958
Mehmet Dal
  1. COVID-19 clinical course and blood groups: Turkish population-based study Turk J Med Sci. 2021 08 30; 51(4):1659-1664.
    View in: PubMed
    Score: 0.241
  2. Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients. Transfus Apher Sci. 2021 Dec; 60(6):103237.
    View in: PubMed
    Score: 0.241
  3. Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci. 2021 02; 60(1):103017.
    View in: PubMed
    Score: 0.229
  4. The outcome ofancy. COVID-19 in patients with hematological malign J Med Virol. 2021 03; 93(3):1255.
    View in: PubMed
    Score: 0.228
  5. COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2021 04; 56(4):952-955.
    View in: PubMed
    Score: 0.228
  6. Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci. 2021 Feb; 60(1):102955.
    View in: PubMed
    Score: 0.226
  7. Convalescent plasma therapy in patients with COVID-19. J Clin Apher. 2020 Aug; 35(4):367-373.
    View in: PubMed
    Score: 0.223
  8. Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption. Transfus Apher Sci. 2020 Aug; 59(4):102855.
    View in: PubMed
    Score: 0.222
  9. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment. Medicine (Baltimore). 2019 Jul; 98(30):e16482.
    View in: PubMed
    Score: 0.208
  10. Impact of Guideline-Driven Approach in Follow-Up of Long-Term Complications After Allogeneic Hematopoietic Cell Transplant: Single Center Experience. Exp Clin Transplant. 2020 06; 18(3):359-367.
    View in: PubMed
    Score: 0.197
  11. Coexistence of chronic lymphocytic leukemia and multiple myeloma, do the roots of these entities originate from the same place? Clin Case Rep. 2017 06; 5(6):1032-1033.
    View in: PubMed
    Score: 0.178
  12. Risk Adapted Management of Febrile Neutrepenia and Early Cessation of Empirical Antibiotherapy in Hematopoietic Stem Cell Transplantation Setting. Balkan Med J. 2017 Apr 05; 34(2):132-139.
    View in: PubMed
    Score: 0.178
  13. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers. Intern Emerg Med. 2022 01; 17(1):135-139.
    View in: PubMed
    Score: 0.059
  14. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2020 Oct; 26(7):1676-1682.
    View in: PubMed
    Score: 0.056
  15. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021 02; 93(2):1099-1104.
    View in: PubMed
    Score: 0.056
  16. Splenic Marginal Zone Lymphoma in Turkey: Association with Hepatitis B Instead of Hepatitis C Virus as an Etiologic and Possible Prognostic Factor - A Multicenter Cohort Study Turk J Haematol. 2020 05 06; 37(2):84-90.
    View in: PubMed
    Score: 0.053
  17. Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy. J Chemother. 2018 Feb; 30(1):44-48.
    View in: PubMed
    Score: 0.046
  18. Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience. Hematol Oncol. 2018 Feb; 36(1):116-120.
    View in: PubMed
    Score: 0.045
  19. BK Virus-associated Hemorrhagic Cystitis in Patients with Allogeneic Hematopoietic Cell Transplantation: Report of Three Cases. Hematol Rep. 2017 Jun 01; 9(2):7205.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.